š° Full Story
On April 17, 2026, the U.S. International Trade Commission declined to review an administrative law judgeās March finding that Appleās redesigned bloodāoxygen feature does not infringe patents held by medtech firm Masimo, effectively closing Masimoās bid to reinstate an import ban on Apple Watch models.
The decision follows a 2023 ITC finding that briefly blocked imports of the Series 9 and Ultra 2, prompting Apple to remove and then reintroduce a reworked bloodāoxygen capability in August 2025 that displays readings on paired iPhones rather than directly on the watch.
Masimo, owned by Danaher, has separately won a $634 million jury verdict in a California case and continues other challenges, including litigation over U.S. Customsā approval of Appleās redesign.
Masimo can appeal the ITC decision to the U.S. Court of Appeals for the Federal Circuit; Apple has said it will appeal the November damages ruling.








š¬ Commentary